阿兹海默症人体肠道微生物组库构建

Alzheimer’s Disease(AD) is a neuronal degeneration disease with the highest incidence in the world. Patients with AD suffer abbreviated life with deficit of cognition and memory. Mechanism of gut microbiota in neuronal degeneration of AD lack studies compared with other degenerative disease such as Parkinson's Disease, multiple sclerosis, etc. Our research accumulates gut microbes from patient with cognition impairment and volunteers at the same age as control. We exclude patients with symptoms not related to AD based on clinical examination and estimation with CRF then we group them on account of neuronal degeneration. Those will form the first human gut microbe library for AD research in China. Then we will extract DNA from gut microbes and 16s rRNA sequencing will be done for its genomes. Then we analyze results with UTO, PCOA, metagemonic analysis. Also, we will examine inflammatory protein with ELISA and neurotransmitter with HPLC. Based on results of clinical diagnosis and CRF, genomics data, and biochemistry data, we can explore the genomics and metabolomics dynamic of gut microbiota with neurodegeneration of Alzheimer's Disease and we can determine the concrete microbes playing a role in AD neurodegeneration.

阿兹海默症是目前全球罹患人数最多的神经退行性疾病。严重损害患者寿命及其认知，记忆能力。相较其他神经退行性疾病如帕金森病，多发性硬化症等，肠道微生物组对其神经退变过程的机制目前缺乏研究。本项目通过收集认知障碍患者及同年龄正常志愿者粪便样本，根据临床诊断及量表评估，排除其他疾病可能性，并对神经退变程度进行分组，形成国内首个阿兹海默症患者肠道微生物库。肠道微生物提取DNA进行16s rRNA测序，然后进行UTO，PCOA，metagenomic分析。同时通过酶联免疫吸附试验检测样本内炎症蛋白水平，通过高效液相色谱检测样本内神经递质水平。综合诊断评估结果，基因组学结果，生物化学实验结果，探究阿兹海默症神经退变过程中肠道微生物基因表达及代谢水平变化，明确与阿兹海默症神经退变相关的具体肠道微生物。

本项目通过收集认知障碍患者及同年龄正常志愿者粪便样本，根据临床诊断及量表评估 ，排除其他疾病可能性，并对疾病退行程度进行分组，形成国内首个阿兹海默症患者肠道微生物库。 MCI实验组：51人，年龄58.0+4.7，MMSE评分24.6+3.3，MOCA评分18.8+4.5；对照组36人，年龄56.4+3.9，MMSE评分28.2+0.9，MOCA评分27.4+1.2。 AD实验组：49人，年龄65.4+6.8，MMSE评分19.8+2.4，MOCA评分16.7+3.5；对照组28人，年龄64.3+2.5，MMSE评分27.3+1.0，MOCA评分26.9+0.7。样品已进行16sRNA测序，并取得相关实验结果。